Simultaneous determination of moxifloxacin and H2 receptor antagonist in pharmaceutical dosage formulations by RP-HPLC: application to in vitro drug interactions

Sultana, Najma; Akhtar, Mahwish; Shamim, Sana; Gul, Somia; Arayne, M. Saeed

doi:10.1590/s0100-40422011000400022

Cited by 17 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are evidence of use of adjunct antibiotics like fluoroquinolones with anticancer drugs enhancing the cytotoxic effects while, at the same time, decreasing chemotherapy-induced proinflammatory cytokine secretion from cells, which may be harmful during chemotherapeutic treatment 13,14,15 . Few spectrophotometric methods [16][17][18][19][20][21] and High-Performance Liquid Chromatography (HPLC) [22][23][24][25][26][27][28][29] have been reported for the determination of MOX and VIN in single or combined pharmaceutical dosage forms or biological fluids. But none of these methods demonstrate the simultaneous estimation of these two drugs in combination by a derivative method in the pharmaceutical dosage form.…”

Section: Fig 2: Structure Of Moxifloxacin Hydro-chloridementioning

confidence: 99%

“…A drug which has narrow therapeutic range need regular monitoring of drug plasma concentration 4,5 . In continuation of our previous simultaneous estimation of Moxifloxacin with Doxorubicin hydrochloride, Imatinib mesylate and Vinblastine sulfate by vierodt's method 3,[20][21][22][23][24][25][26][27][28][29][30][31] in the present paper, secondorder derivative UV spectrophotometry was used for the simultaneous estimation of VIN and MOX.…”

Section: Fig 2: Structure Of Moxifloxacin Hydro-chloridementioning

confidence: 99%

See 1 more Smart Citation

Untitled

2019

IJPSR

View full text Add to dashboard Cite

Objective: To develop a simple, accurate and precise method for the simultaneous estimation of Moxifloxacin hydrochloride (MOX) and Vinblastine sulfate (VIN). Methods: The normal spectrum of VIN and MOX were converted to its second derivative spectrum and the amplitude minima of VIN and MOX were measured at 214 nm and 297 nm, respectively. MOX and VIN solution were simultaneously determined in 0.1M HCl at 297 nm and 214 nm. Results: The amplitude of MOX and VIN were found to be more distinct in 0.1M HCl with compared to water, methanol and 0.1M NaOH (order = 2 and Δλ=1). Linearity was obtained over the range 1-8 μg/ml and 3-24 μg/ml with a lower limit of quantitation of 1.7 μg/ml and 0.4 μg/ml for MOX and VIN, respectively. For each level of samples, interand intra-day precision (% RSD) was <2.1% and <2.3%for MOX and < 2.3 and <2.7 % for VIN, respectively. The mean recovery of MOX and VIN were in the range 99.98%-103.1%and 101.03%-104.3%, respectively. The developed method was validated as per ICH guidelines for parameters like linearity, accuracy, method precision, and ruggedness. Conclusion: The results obtained were well within the acceptable criteria. The method can be used for routine analysis of MOX and VIN.

show abstract

Section: Fig 2: Structure Of Moxifloxacin Hydro-chloridementioning

confidence: 99%

Section: Fig 2: Structure Of Moxifloxacin Hydro-chloridementioning

confidence: 99%

Untitled

2019

IJPSR

View full text Add to dashboard Cite

show abstract

“…Numerous chromatographic methods have been reported in the literature for the determination of Moxifloxacin [15][16][17] , simvastatin [18][19] and atorvastatin [20][21] alone or concurrently with other drugs but no method is reported for the simultaneous determination of the above mentioned drugs using RP-HPLC. The objective of this study was to develop an accurate, sensitive and reproducible method for Reverse Phase-HPLC.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Quantitation of Moxifloxacin and Statins Inapi by Rp-HPLC

Qamar

Sattar

Sana

et al. 2019

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

Moxifloxacin belongs to broad spectrum flouroquinolone class and having antimicrobial activity. A rapid, cheap, reliable and accurate method has been developed and validated for the simultaneous analysis of Moxifloxacin with statin in active and in dosage formulation. Chromatographic separation was carried out using Purospher star C18 (5 µm, 25 × 0.46 cm) column at room temperature (25± 2 o C) with flow rate of 1 ml /min, detector was set at 250nm and mobile Phase was 95:5 v/v methanol: water. The correlation coefficient of both drugs was found to be > 0.990 and 0.999. Small sample is taken for limit of quantification.

show abstract

“…Many analytical methods have been developed to determine statins, specifically rosuvastatin alone, such as liquid chromatography (Pasha et al ., ), or in combination with other drugs over the past decade as with simvastatin and pravastatin sodium (Chaudhari et al ., ), atorvastatin, lovastatin, pravastatin and simvastatin (Pasha et al ., ), with finofibrate (Sharma and Bhandari, ), with atenolol, spironolactone, glibenclamide and naproxen sodium (Sultana et al ., ), with pioglitazone, gliquidone and simvastatin, with simvastatin, atorvastatin, pravastatin and ceftriaxone (Arayne et al ., ), with diltiazem, atorvastatin and simvastatin (Sultana et al ., ), with lisinopril, pravastatin and atorvastatin (Sultana et al ., ), with captopril, atorvastatin and simvastatin (Sultana et al ., ), with Angiotensin Converting Enzyme (ACE) inhibitors (Arayne et al ., ) and with Non Steroidal Antiinflammatory Drugs (NSAIDs) (Arayne et al ., ; Sultana et al ., ). A number of spectrophotometric and RP‐HPLC methods have been reported for the quantitative determination of fluoroquinolones in pharmaceutical formulations and spiked human serum (Joshi, ; Belal et al ., ; Santoro et al ., ; Arayne et al ., ; Sultana et al ., ) as well as simultaneous determination of quinolones with other co‐administered drugs (Gul et al ., ; Sultana et al ., ,,, ).…”

Section: Introductionmentioning

confidence: 99%

Facile LC‐UV methods for simultaneous monitoring of ciprofloxacin and rosuvastatin in API, formulations and human serum

Arayne

Sultana

Tabassum

2014

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

An efficient, selective and cost-effective liquid chromatographic assay was developed and validated for the simultaneous quantification of ciprofloxacin and rosuvastatin in Active Pharmaceutical Ingredients (API), pharmaceutical formulations and in human serum. The chromatographic system consisted of mobile phase methanol-water, 90:10 v/v at pH 3.0 adjusted with o-phosphoric acid, pumped at 1.0 mL/min through a prepacked Purospher Star C18 (5 µm, 25 × 0.46 cm) column and effluent was monitored at the isosbestic point (255 nm) as well as at the λmax of individual drugs (243 and 271 nm). The method was validated over a linear concentration range of 0.25-15 µg/mL for ciprofloxacin and 0.33-20 µg/mL for rosuvastatin (r(2) ≥ 0.999). The ranges of reliable response (limits of detection and quantitation) for ciprofloxacin were 3-15 and 9-45 ng/mL and 17-29 and 52-88 ng/mL, respectively, for rosuvastatin in all API, pharmaceutical formulations and human serum. Analytical recovery from human serum was >98% and relative standard deviation (RSD) was <2. The accuracies were 97.13-102.55 and 97.41-101.31% and precisions in RSD were 0.04-1.90 and 0.02-1.23% for ciprofloxacin and rosuvastatin, respectively. No matrix interferences, ion suppression/enhancement and carry-over were detected. The total assay run time was less than 5 min. In another study, for optimum performance the detector was programmed for multiwavelength scanning at the absorption maxima of each component. Consequently, the linearity range was improved and limit of detection and quantitation values were down to 1-4 and 4-12 ng/mL for ciprofloxacin and 3-5 and 9-15 ng/mL for rosuvastatin, respectively. The validation parameters fitted ICH guidelines through the isosbestic and individual λmax approach. The small sample volume and simplicity of preparation make this method suitable for use in human serum samples, pharmaceutical formulations, quality control, drug-drug interaction studies, clinical laboratories, drug research centers and forensic medical centers.

show abstract

Simultaneous determination of moxifloxacin and H2 receptor antagonist in pharmaceutical dosage formulations by RP-HPLC: application to in vitro drug interactions

Cited by 17 publications

References 13 publications

Untitled

Untitled

Simultaneous Quantitation of Moxifloxacin and Statins Inapi by Rp-HPLC

Facile LC‐UV methods for simultaneous monitoring of ciprofloxacin and rosuvastatin in API, formulations and human serum

Contact Info

Product

Resources

About